Chronic Prurigo: Current Knowledge, Treatment Strategies, Future Perspectives, and Unmet Needs
DOI:
https://doi.org/10.2340/actadv.v106.44285Keywords:
Prurigo Nodularis, chronic prurigo, pruritus., unmet needs, TreatmentDownloads
References
Müller S, Zeidler C, Ständer S. Chronic prurigo including prurigo nodularis: new insights and treatments. Am J Clin Dermatol 2024; 25: 15–33. DOI: https://doi.org/10.1007/s40257-023-00818-z
Ständer S, Pereira MP, Berger TM, Zeidler C, Augustin M, Bobko S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch 2020; 5: e42. DOI: https://doi.org/10.1097/itx.0000000000000042
Mahmoud O, Oladipo O, Mahmoud RH, Yosipovitch G. Itch: from the skin to the brain – peripheral and central neural sensitization in chronic itch. Front Mol Neurosci 2023; 16: 1272230. DOI: https://doi.org/10.3389/fnmol.2023.1272230
Parthasarathy V, Yosipovitch G, Kwatra SG. Pathogenesis of prurigo nodularis: current perspectives and future directions. Front Med (Lausanne) 2022; 9: 1011142. DOI: https://doi.org/10.3389/fmed.2022.1011142
Rodriguez D, Kwatra SG, Dias-Barbosa C, Zeng F, Jabbar Lopez ZK, Piketty C, et al. Patient perspectives on living with severe prurigo nodularis. JAMA Dermatol 2023; 1205–1212. DOI: https://doi.org/10.1001/jamadermatol.2023.3251
Chisolm SS. A review of the current management and burden of prurigo nodularis in the United States. Am J Manag Care 2023; 29: S63–S72. DOI: https://doi.org/10.37765/ajmc.2023.89366
Yin M, Yang C, Guo Y, Yang X, Dou X. Comorbidities of chronic prurigo: a systematic review and meta-analysis. Dermatology 2024; 240: 32–41. DOI: https://doi.org/10.1159/000534660
Morgan CL, Thomas M, Heywood BR, Ständer S, Kwatra SG, Jabbar-Lopez ZK, et al. Incident comorbidity, resource use, and all-cause mortality associated with prurigo nodularis: a United Kingdom retrospective database analysis. JID Innov 2023; 3: 100233. DOI: https://doi.org/10.1016/j.xjidi.2023.100233
Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol 2021; 84: 747–760. DOI: https://doi.org/10.1016/j.jaad.2020.07.025
Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29: 1180–1190. DOI: https://doi.org/10.1038/s41591-023-02320-9
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase 3 trial. JAMA Dermatol 2025; 161: 147–156. DOI: https://doi.org/10.1001/jamadermatol.2024.4796
Paganini C, Talamonti M, Maffei V, Di Raimondo C, Bianchi L, Galluzzo M. Real-world effectiveness of dupilumab for prurigo nodularis. J Clin Med 2024; 13: 878. DOI: https://doi.org/10.3390/jcm13030878
Bianco M, D’Oria F, Falcidia C, Foggi G, Matteodo E, Di Giulio S, et al. New and emerging biologics and JAK inhibitors for the treatment of prurigo nodularis: a narrative review. Medicina (Kaunas) 2025; 61: 631. DOI: https://doi.org/10.3390/medicina61040631
Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomized, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine 2023; 57: 101826. DOI: https://doi.org/10.1016/j.eclinm.2023.101826
ClinicalTrials.gov. Study of rocatinlimab in prurigo nodularis (NCT06527404). ClinicalTrials.gov [Accessed March 2025]. Available from: www.clinicaltrials.gov/study/NCT06527404
Published
How to Cite
License
Copyright (c) 2026 Ignasi Figueras, Esther Serra-Baldrich, Sonja Ständer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
